Actively Recruiting
Prediction Model for Response to Biologics and Small Molecular Agent for UC
Led by Asan Medical Center · Updated on 2022-02-15
300
Participants Needed
1
Research Sites
255 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This prospective observational study is going to develop and validate a prediction model of response to biologic agents and small molecular agents for Korean patients with ulcerative colitis.
CONDITIONS
Official Title
Prediction Model for Response to Biologics and Small Molecular Agent for UC
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with an established diagnosis of ulcerative colitis based on clinical symptoms, endoscopic features and histopathologic features
- Patients who are going to receive vedolizumab, ustekinumab, or tofacitinib treatment
You will not qualify if you...
- Not Korean ethnicity by family history
- Inflammatory Bowel Disease Unclassified
- Patients who already received colectomy due to ulcerative colitis
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Asan Medical Center
Seoul, South Korea, 05505
Actively Recruiting
Research Team
B
Byong Duk Ye, MD, PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here